Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Dominican Republic | India | Lebanon | Turkey
Approved Indications: None
Known Adverse Events: None
Company: Jiangsu Aosaikang
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description

Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Duodenal Ulcer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20170066 | P3 |
Recruiting |
Duodenal Ulcer |
None |